Targeting RAGE in sepsis

The receptor of advanced glycation endproducts (RAGE) is a multiligand receptor that upon activation causes sustained activation of multiple inflammatory pathways. Recent evidence, summarized in a review by Bopp and colleagues in this issue of Critical Care, has implicated RAGE as a potential therap...

Descripción completa

Detalles Bibliográficos
Autores principales: van Zoelen, Marieke AD, van der Poll, Tom
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374639/
https://www.ncbi.nlm.nih.gov/pubmed/18254937
http://dx.doi.org/10.1186/cc6187
_version_ 1782154501107482624
author van Zoelen, Marieke AD
van der Poll, Tom
author_facet van Zoelen, Marieke AD
van der Poll, Tom
author_sort van Zoelen, Marieke AD
collection PubMed
description The receptor of advanced glycation endproducts (RAGE) is a multiligand receptor that upon activation causes sustained activation of multiple inflammatory pathways. Recent evidence, summarized in a review by Bopp and colleagues in this issue of Critical Care, has implicated RAGE as a potential therapeutic target in sepsis. Here, we discuss several open issues that need to be addressed before anti-RAGE strategies can enter the sepsis clinical trial arena.
format Text
id pubmed-2374639
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-23746392008-05-09 Targeting RAGE in sepsis van Zoelen, Marieke AD van der Poll, Tom Crit Care Commentary The receptor of advanced glycation endproducts (RAGE) is a multiligand receptor that upon activation causes sustained activation of multiple inflammatory pathways. Recent evidence, summarized in a review by Bopp and colleagues in this issue of Critical Care, has implicated RAGE as a potential therapeutic target in sepsis. Here, we discuss several open issues that need to be addressed before anti-RAGE strategies can enter the sepsis clinical trial arena. BioMed Central 2008 2008-01-11 /pmc/articles/PMC2374639/ /pubmed/18254937 http://dx.doi.org/10.1186/cc6187 Text en Copyright © 2008 BioMed Central Ltd
spellingShingle Commentary
van Zoelen, Marieke AD
van der Poll, Tom
Targeting RAGE in sepsis
title Targeting RAGE in sepsis
title_full Targeting RAGE in sepsis
title_fullStr Targeting RAGE in sepsis
title_full_unstemmed Targeting RAGE in sepsis
title_short Targeting RAGE in sepsis
title_sort targeting rage in sepsis
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374639/
https://www.ncbi.nlm.nih.gov/pubmed/18254937
http://dx.doi.org/10.1186/cc6187
work_keys_str_mv AT vanzoelenmariekead targetingrageinsepsis
AT vanderpolltom targetingrageinsepsis

Ejemplares similares